Sign in Subscribe

Archive

A collection of 24 issues

Latest

Tirzepatide: The Dual GIP/GLP-1 Agonist Revolutionizing Weight Management

Tirzepatide: The Dual GIP/GLP-1 Agonist Revolutionizing Weight Management Key Takeaways - Tirzepatide is the first dual GIP/GLP-1 receptor agonist, targeting two incretin pathways simultaneously - Clinical trials show 15-22% weight loss over 72 weeks, superior to single GLP-1 agonists - FDA-approved as Mounjaro for diabetes and Zepbound for

Semaglutide: The Science Behind the GLP-1 Revolution

semaglutide-the-science-behind-the-glp-1-revolution">Semaglutide: The Science Behind the GLP-1 Revolution Key Takeaways - Semaglutide mimics GLP-1 hormone, slowing gastric emptying and reducing appetite through central nervous system pathways - Clinical trials show 15-20% body weight reduction in non-diabetic adults at 2.4mg weekly doses - Common side effects include nausea

TB-500: The Complete Guide to Thymosin Beta-4 for Recovery and Healing

TB-500: The Complete Guide to Thymosin Beta-4 for Recovery and Healing Key Takeaways - TB-500 is a synthetic fragment of thymosin beta-4 that promotes cellular repair and angiogenesis - Research suggests dosing ranges of 2-10mg per week, typically administered subcutaneously - Animal studies show significant wound healing and tissue regeneration

BPC-157: The Complete Guide to the Body Protection Compound

BPC-157: The Complete Guide to the Body Protection Compound Key Takeaways - BPC-157 is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice - Research suggests potential benefits for tissue repair, with most studies conducted in animal models - Common dosing ranges from 250-500 mcg